New drug plus standard chemo for untreated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug (TRS005) combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) as a first treatment for people with CD20-positive DLBCL. The goal is to see if this combination is safe and effective in controlling the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with CD20-positive DLBCL and have not yet received any treatment for it.
- You must have at least one measurable lymphoma lesion (a lymph node larger than 1.5 cm or a tumor outside the nodes larger than 1 cm).
- You must have an IPI score of 2 to 5, meaning your lymphoma is considered intermediate or high risk.
- You must be able to care for yourself (ECOG performance status 0–2) and have a life expectancy of at least 6 months.
- Your organ function (kidney, liver, heart, etc.) must be adequate, and you must be willing to use effective birth control during the study if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
This trial tests whether adding a new targeted drug called birelentinib to the standard chemotherapy combination (R-CHOP) helps people with newly diagnosed aggressive lymphoma. It aims to improve the chances of remission and reduce the risk of the lymphoma coming back.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This trial tests a new drug called TRS005 for people with a type of lymphoma (CD20-positive DLBCL) that has not responded to at least two previous treatments. The goal is to see if this drug can help shrink tumors and slow the disease.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.